Vitamin D and quality of life in patients with hashimoto thyroiditis

Zvezdana Jemuovic; Djurovic Marina Nikolic; Djurdjevic Sandra Pekic; Dragana Miljic; Marko Stojanovic; Ana Petakov; Jevremovic Ljiljana Dimitrijevic; Ivana Cekic; Ivan Jevtic; Milan Petakov

doi:10.1530/endoabs.99.P585

P585

Prev Next

Section Contents Cite

Endocrine Abstracts (2024) 99 P585 | DOI: 10.1530/endoabs.99.P585

ECE2024 Poster Presentations Late-Breaking (77 abstracts)

Vitamin D and quality of life in patients with hashimoto thyroiditis

Zvezdana Jemuovic ¹ , Marina Nikolic Djurovic ¹ , Sandra Pekic Djurdjevic ¹ , Dragana Miljic ¹ , Marko Stojanovic ¹ , Ana Petakov ¹ , Ljiljana Dimitrijevic Jevremovic ² , Ivana Cekic ¹ , Ivan Jevtic ¹ & Milan Petakov ¹

Err

Author affiliations

¹Clinic for Endocrinology, Diabetes and Diseases of Metabolism, University Clinical Center, Serbia; ²General Hospital Krusevac, Krusevac, Serbia

Introduction: Hashimoto thyroiditis (HT), chronic autoimmune disease, is related with impaired quality of life (QoL) regardless of euthyroid state. Some studies showed decreased levels of vitamin D in patients with HT which implies there is a relationship between vitamin D deficiency and HT. It remains unclear whether decreased levels of vitamin D are result of autoimmune process or are part of its cause.

Aim: To investigate effect of vitamin D levels on QoL in patients with HT on levothyroxine therapy (LT4).

Methods: Cross-sectional, case control study with 42 HT patients (mean age 47.14±13.25) on long levothyroxine replacement and 22 euthyroid healthy controls, matched for age, sex and educational level, were included. HT patients were divided into 2 groups, 25 patients with normal vitamin D levels (nVD) and 22 patients with vitamin D deficiency (dVD). Measurement of TSH, FT4, anti-TPO, anti-Tg, Vitamin D was done. Evaluation of QoL was evaluated by QoL questionnaire - SF36. Fisher’s ANOVA analysis was used to compare means between (sub)groups.

Results: HT patients had higher TSH levels in both groups (nVD vs dVD) vs control (3.70±2.88 vs 2.62±1.76 vs 1.85±1.18mIU/l, P=0.021) and higher anti-TPO (nVD: 2638.78±3065.84 vs 2458.83±2335.37 vs 64.50±170.82mIU/l, P=0.001). Vitamin D levels were lower in both HT groups (nVD vs dVD) vs control (31.24±6.96 vs 16.83±5.12 vs 38,40±15.92ng/ml, P=0.000). Patients in both nVD and dVD groups reported worse general health – Scale 4 compared vs control (68.24±16.59 vs 58.41±18.44 vs 73.36±15.05, P=0.014), physical health – Dimension A (60.27±18.46 vs 70.40±18.53 vs 73.73±17.08, P=0.042), mental health – Dimension B (59.23±20.47 vs 67.16±17.50 vs 73.86±17.03, P=0.036) and Total SF35 score (60.86±20.66 vs 69.72±17.54 vs 74.86±16.84, P=0.044).

Conclusion: Patients with HT and vitamin D deficiency had statistically significant worse quality of life compared to healthy control. Future studies with larger cohorts and in longer observation periods are needed to clarify role of vitamin D in quality of life in patients with Hashimoto thyroiditis.